Use of acenocoumarol in cardioembolic stroke: an evidence-based review
DOI:
https://doi.org/10.18203/2349-3933.ijam20240367Keywords:
Acenocoumarol, Atrial fibrillation, International normalized ratio, NOACs, VKAs, WarfarinAbstract
Stroke is the leading cause of long-term disability and the second most common cause of death worldwide. Nearly two-thirds of all strokes represent cerebral ischemia, of which about 15%-30% are of cardioembolic origin. Atrial fibrillation accounts for about 60% of all cardioembolic strokes. Current clinical evidence suggests that oral anticoagulant therapy can prevent around 70% of strokes in patients with atrial fibrillation. Oral anticoagulation therapy is preferred over antiplatelet therapy in patients with cardioembolic stroke. Vitamin K antagonists (VKAs) and nonvitamin K antagonist oral anticoagulants (NOACs) are routinely prescribed oral anticoagulants in patients at risk of stroke; however, there are specific indications where VKA use surpasses NOAC use or there are conditions where NOACs are contraindicated. A group of experts revisited the role of oral anticoagulants in the management of cardioembolic stroke in India with emphasis on VKA, specifically acenocoumarol. This article discusses various aspects of anticoagulation therapy, including the timing of initiation and patient monitoring, in patients with cardioembolic stroke with reference to current clinical evidence and expert opinion based on Indian clinical experience.
Metrics
References
Nepal R, Choudhary M, Dhungana S, Katwal S, Khanal S, Bista M et al. Prevalence and major cardiac causes of cardio-embolic stroke and in-hospital mortality in Eastern Nepal. J Clin Prev Cardiol. 2020;9(1):19-24.
Kamel H, Healey JS. Cardioembolic stroke. Circ Res. 2017;120(3):514-26.
Jurjāns K, Cērpa M, Baborikina A, Kalējs O, Miglāne E. Impact of anticoagulants in reducing mortality and
disability in cardioembolic stroke patients. Medicina. 2022;58(10):1323.
Leary MC, Caplan LR. Cardioembolic stroke: An update on etiology, diagnosis and management. Ann Indian Acad Neurol. 2008;11(5):S52-S63.
Wessler BS, Kent DM. Controversies in cardioembolic stroke. Curr Treat Options Cardio Med. 2015;17(1):358.
Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non‐valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;3:CD006186.
Altiok E, Marx N. Oral Anticoagulation. Dtsch Arztebl Int. 2018;115(46):776-83.
Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J. 2017;38(12):852-9.
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-91.
Sacchetti DC, Furie KL, Yaghi S. Cardioembolic stroke: Mechanisms and therapeutics. Semin Neurol. 2017;37(3):326-38.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-110.
Yaghi S, Trivedi T, Henninger N, Giles J, Liu A, Nagy M et al. Anticoagulation timing in cardioembolic stroke and recurrent event risk. Ann Neurol. 2020;88(4):807-16.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962.
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231-42.
Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967-77.
Hylek EM. Apixaban for end-stage kidney disease: More questions for the randomized trials. Circulation. 2018;138(15):1534-6.
Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115(1):15-20.
Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III): Position paper of the ESC working group on thrombosis- task force on anticoagulants in heart disease. Thromb Haemost. 2013;110(12):1087.
Trailokya A. Acenocoumarol in thromoembolic disorders. Cardiol Pharmacol. 2015;4(4):157.
Sinthrome 1 mg Tablets-Summary of Product Characteristics (SmPC) - (EMC) Available at: https://www.medicines.org.uk/emc/product/2058. Accessed on 4 December 2022.
Lip GYH, Skjøth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65(14):1385-94.
Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46.
Lengyel M, SPORTIF-III Altanulmány Vizsgálói. Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?. Orv Hetil. 2004;145(52):2619-21.
Kulo A, Kusturica J, Kapić E, Becić F, Rakanović-Todić M, Burnazović-Ristić L et al. Better stability of acenocoumarol compared to warfarin treatment in one-year observational, clinical study in patients with nonvalvular atrial fibrillation. Med Glas. 2011;8(1):9-14.
Trailokya A, Hiremath JS, Sawhney J, Mishra YK, Kanhere V, Srinivasa R et al. Acenocoumarol: A review of anticoagulant efficacy and safety. J Assoc Physicians India. 2016;64(2):88-93.
Menichelli D, Poli D, Antonucci E, Cammisotto V, Testa S, Pignatelli P et al. Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves: Insights from the nationwide PLECTRUM study. Molecules. 2021;26(5):1425.
Beinema M, Brouwers JRBJ, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost. 2008;100(6):1052-7.
Barcellona D, Vannini ML, Fenu L, Balestrieri C, Marongiu F. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Thromb Haemost 1998;80(6):899-902.
Alias SM, Nair VS, Byju P, Pai PG, Reghu R. A comparative study on the effect of Warfarin v/s Acenocoumarol in patients with atrial fibrillation. Res J Pharm Technol. 2021;14(1):1-5.
Trullas-Vila JC, Bisbe-Company J, Freitas-Ramírez A, Soler-Simon S, Bisbe-Company V, Roncero-Vidal JM et al. Ten-year experience with acenocoumarol treatment in an ambulatory cohort of Spanish patients. J Thromb Thrombolysis. 2009;28(4):436-43.
Zharkova TV, Ataullakhanova DM, Bykova ES, Kropacheva ES, Dobrovol’skiĭ AB, Titaeva EV et al. Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation. Kardiologiia. 2007;47(6):31-6.
Kulo A, Mulabegović N, Kusturica J, Hadžić H, Burnazović-Ristić L, Rakanović-Todić M et al. Outpatient management of oral anticoagulation therapy in patients with nonvalvular atrial fibrillation. Bosn J Basic Med Sci. 2009;9(4):313-9.
Rodríguez‐Bernal CL, Santa‐Ana‐Téllez Y, García‐Sempere A, Hurtado I, Peiró S, Sanfélix‐Gimeno G. Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population‐based propensity‐weighted cohort study. Br J Clin Pharmacol. 2021;87(2):632-43.
Altman R, Rouvier J, Gurfinkel E, D’Ortencio O, Manzanel R, De La Fuente L et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1991;101(3):427-31.
Tramarin R, Pozzoli M, Febo O, Opasich C, Colombo E, Cobelli F et al. Two-dimensional echocardiographic assessment of anticoagulant therapy in left ventricular thrombosis early after acute myocardial infarction. Eur Heart J. 1986;7(6):482-92.
Woods A, Vargas J, Berri G, Kreutzer G, Meschengieser S, Lazzari MA. Antithrombotic therapy in children and adolescents. Thromb Res. 1986;42(3):289-301.
Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP et al. Acenocoumarol therapy in pediatric patients. J Thromb Haemost. 2003;1(8):1740-3.
Van der Pol S, Jacobs MS, Meijer K, Piersma-Wichers MG, Tieleman RG, Postma MJ et al. Perioperative bridging of vitamin K antagonist treatment in patients with atrial fibrillation: only a very small group of patients benefits. Europace. 2019;21(5):716-23.
Van Leeuwen Y, Rosendaal FR, van der Meer FJM. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon. Thromb Res 2008;123(2):225-30.
Freixa R, Blanch P, Ibernón M, Padró J, Delso J, Sobrepera JL et al. Identification of factors responsible for oral over-anticoagulation in outpatients with heart disease. Rev Esp Cardiol 2003;56(1):65-72.
Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet. 1996;348(9025):423-8.
Visser LE, Penning-van Bees FJA, Kasbergen AAH, De Smet PAGM, Vulto AG, Hofman A et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost. 2002;88(5):705-10.
Penning-van Beest FJ, Van Meegen E, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther. 2001;69(6):451-7.
Sarode R, Milling TJ, Refaai MA, Mangione A, Schneider A, Durn BL et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-43.
Steiner T, Poli S, Griebe M, Hüsing J, Hajda J, Freiberger A et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566-73.
Downloads
Published
How to Cite
Issue
Section
